Acquisition Opportunity Brightech International was acquired by Everest Clinical Research Services in December 2022, suggesting a potential alignment of client bases and a path to cross-sell senior clinical data solutions, biostatistics, SAS programming, and regulatory strategy services.

Full Service CRO As a long-standing boutique CRO specializing in clinical data management, biostatistics, programming, medical writing, and regulatory strategy, Brightech offers a comprehensive suite that can complement Everest’s capabilities or enable joint bids to large pharma and biotech clients seeking end-to-end data solutions.

Proprietary Platform The company markets a sophisticated proprietary eClinical Suite (CIMS) for Clinical Information Management, presenting a potential upsell path for customers needing integrated data capture, management, and regulatory submission workflows.

Long-Term Relationships With 25 plus long-term clients and a track record of NDA approvals, Brightech demonstrates stickiness and potential for renewal-based revenue, suggesting value in expanding existing client engagements and offering additional services such as regulatory submissions and medical writing.

Growth and Outreach Operating with a lean team (11-50 employees) and mid-market revenue, Brightech presents an opportunity to upsell scaled services, CDISC specialization, and data intelligence offerings to mid-to-large biotech companies seeking efficient data solutions and faster time-to-submission.